


REPUBLIC OF THE PHILIPPINES Department Of Health





NOTICE OF AWARD

September 13, 2023

PHILCARE PHARMA, INC.

#3 Mahogany St., Agapito Subdivision,

Santolan, Pasig City

Tel No.: +632 8682-3466; 09982094169 Email: regulatory3@philcarepharma.com

Sir / Madam:

Please be advised that based on the results of the Public Bidding conducted by the National Center for Mental Health for the Supply and Delivery of Drugs and Medicines - Additional CY 2023, the following items are hereby awarded to your company:

NO.	QTY	UNIT	ITEM CODE / SPECIFICATION	UNIT PRICE	TOTAL PRICE
1	400	ampule	DM-36 Glyceryl Trinitrate 1mg/ml 10ml Brand: Nitrosan 1mg/ml (10mg/10ml) Solution for IV Infusion Origin: India	₱ 436.80	₱ 174,720.00
2	400	ampule	DM-88 Vasopressin 20 IU ml Brand: Presson 20IU/ml Solution for Injection Origin: Ukraine	1,654.00	661,600.00
TOTAL AMOUNT:					₱ 836,320.00

You are hereby required to submit the following within ten (10) calendar days:

Notarized Contract Agreement Form (Legal Size) for the Public Bidding for the Supply and Delivery of Drugs and Medicines - Additional CY 2023

NOTE: The signatory shall be NOEL V. REYES, MD, FPPA, MMHoA, MEDICAL CENTER CHIEF II; and

- Notarized Performance Securing Declaration; or
- Performance Security in any forms and amount stipulated below:

A.	Cash or Cashier's / Manager's Check	Five Percent (5%) of the Total Contract Price
	Bank Guarantee	

"There is no Health without Mental Health"







B. Surety Bond callable upon demand issued by a surety or insurance company duly certified by Insurance Commission / GSIS

Thirty Percent (30%) of the Total Contract Price

LABELLING:

For each box, bottle, and corrugated carton, the following should be legibility imprint:

"Philippine Government Property
Department of Health
NOT FOR SALE"

Failure to provide any of the above-mentioned requirements shall constitute sufficient grounds for cancellation of this Award and forfeiture of the Bid Security.

Truly yours,

NOEL V. REYES, MD, FPPA, MMHoA

Medical Center Chief II

Name & Signature of the Authorized Representative

SEPT. 19 2023

Date and Time